Basic safety assessments indicated that gastrointestinal adverse occasions, generally nausea and diarrhea, have been dose-dependent but commonly moderate and transient. These conclusions recognized the therapeutic window and knowledgeable dose selection for subsequent Period three trials.Continued refinement of formulation and dosing approaches may